These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 33211022)
1. Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial. Dabira ED; Soumare HM; Lindsay SW; Conteh B; Ceesay F; Bradley J; Kositz C; Broekhuizen H; Kandeh B; Fehr AE; Nieto-Sanchez C; Ribera JM; Peeters Grietens K; Smit MR; Drakeley C; Bousema T; Achan J; D'Alessandro U JMIR Res Protoc; 2020 Nov; 9(11):e20904. PubMed ID: 33211022 [TBL] [Abstract][Full Text] [Related]
2. Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia. Dabira ED; Soumare HM; Conteh B; Ceesay F; Ndiath MO; Bradley J; Mohammed N; Kandeh B; Smit MR; Slater H; Peeters Grietens K; Broekhuizen H; Bousema T; Drakeley C; Lindsay SW; Achan J; D'Alessandro U Lancet Infect Dis; 2022 Apr; 22(4):519-528. PubMed ID: 34919831 [TBL] [Abstract][Full Text] [Related]
3. Entomological impact of mass administration of ivermectin and dihydroartemisinin-piperaquine in The Gambia: a cluster-randomized controlled trial. Soumare HM; Dabira ED; Camara MM; Jadama L; Gaye PM; Kanteh S; Jawara EA; Njie AK; Sanneh F; Ndiath MO; Lindsay SW; Conteh B; Ceesay S; Mohammed N; Ooko M; Bradley J; Drakeley C; Erhart A; Bousema T; D'Alessandro U Parasit Vectors; 2022 Nov; 15(1):435. PubMed ID: 36397132 [TBL] [Abstract][Full Text] [Related]
4. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria. Foy BD; Some A; Magalhaes T; Gray L; Rao S; Sougue E; Jackson CL; Kittelson J; Slater HC; Bousema T; Da O; Coulidiaty AGV; Colt M; Wade M; Richards K; Some AF; Dabire RK; Parikh S JMIR Res Protoc; 2023 Mar; 12():e41197. PubMed ID: 36939832 [TBL] [Abstract][Full Text] [Related]
5. Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial. Hutchins H; Bradley J; Pretorius E; Teixeira da Silva E; Vasileva H; Jones RT; Ndiath MO; Dit Massire Soumare H; Mabey D; Nante EJ; Martins C; Logan JG; Slater H; Drakeley C; D'Alessandro U; Rodrigues A; Last AR BMJ Open; 2023 Jul; 13(7):e072347. PubMed ID: 37419638 [TBL] [Abstract][Full Text] [Related]
6. Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial. Kositz C; Vasileva H; Mohammed N; Achan J; Dabira ED; D'Alessandro U; Bradley J; Marks M Malar J; 2024 Feb; 23(1):54. PubMed ID: 38383367 [TBL] [Abstract][Full Text] [Related]
7. From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia. Fehr A; Nieto-Sanchez C; Muela J; Jaiteh F; Ceesay O; Maneh E; Baldeh D; Achan J; Dabira E; Conteh B; Bunders-Aelen J; Smekens T; Broekhuizen H; D'Alessandro U; Peeters Grietens K Malar J; 2021 Apr; 20(1):198. PubMed ID: 33902611 [TBL] [Abstract][Full Text] [Related]
8. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. McLean ARD; Indrasuta C; Khant ZS; Phyo AK; Maung SM; Heaton J; Aung H; Aung Y; Soe K; Swe MMM; von Seidlein L; Tun NN; Tun KM; Day NPJ; Ashley EA; Hlaing T; Kyaw TT; Dondorp AM; Imwong M; White NJ; Smithuis FM Lancet Infect Dis; 2021 Nov; 21(11):1579-1589. PubMed ID: 34147154 [TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
10. Mass drug administration to reduce malaria incidence in a low-to-moderate endemic setting: short-term impact results from a cluster randomised controlled trial in Senegal. Ba Konko Ciré EH; Roh ME; Diallo A; Gadiaga T; Seck A; Thiam S; Gaye S; Diallo I; Lo AC; Diouf E; Ba OG; Gueye AB; Fogelson A; Wu X; Milligan P; Kibuka T; Hama M; Eckert E; Thwing J; Bennett A; Gosling R; Hwang J; Sene D; Ba F; Cissé B; Sturm-Ramirez K; Hsiang MS; Ndiaye JL medRxiv; 2024 Jul; ():. PubMed ID: 39072042 [TBL] [Abstract][Full Text] [Related]
11. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Slater HC; Foy BD; Kobylinski K; Chaccour C; Watson OJ; Hellewell J; Aljayyoussi G; Bousema T; Burrows J; D'Alessandro U; Alout H; Ter Kuile FO; Walker PGT; Ghani AC; Smit MR Lancet Infect Dis; 2020 Apr; 20(4):498-508. PubMed ID: 31948767 [TBL] [Abstract][Full Text] [Related]
12. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission. Morris U; Msellem MI; Mkali H; Islam A; Aydin-Schmidt B; Jovel I; Shija SJ; Khamis M; Ali SM; Hodzic L; Magnusson E; Poirot E; Bennett A; Sachs MC; Tarning J; Mårtensson A; Ali AS; Björkman A BMC Med; 2018 Dec; 16(1):215. PubMed ID: 30526588 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. Smit MR; Ochomo E; Aljayyoussi G; Kwambai T; Abong'o B; Bayoh N; Gimnig J; Samuels A; Desai M; Phillips-Howard PA; Kariuki S; Wang D; Ward S; Ter Kuile FO JMIR Res Protoc; 2016 Nov; 5(4):e213. PubMed ID: 27856406 [TBL] [Abstract][Full Text] [Related]
14. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Eisele TP; Silumbe K; Finn T; Chalwe V; Kamuliwo M; Hamainza B; Moonga H; Bennett A; Yukich J; Keating J; Steketee RW; Miller JM Trials; 2015 Aug; 16():347. PubMed ID: 26268804 [TBL] [Abstract][Full Text] [Related]
15. BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings. Chaccour C; Casellas A; Hammann F; Ruiz-Castillo P; Nicolas P; Montaña J; Mael M; Selvaraj P; Duthaler U; Mrema S; Kakolwa M; Lyimo I; Okumu F; Marathe A; Schürch R; Elobolobo E; Sacoor C; Saute F; Xia K; Jones C; Rist C; Maia M; Rabinovich NR Trials; 2023 Feb; 24(1):128. PubMed ID: 36810194 [TBL] [Abstract][Full Text] [Related]
16. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Sylla M; Kobylinski KC; Gray M; Chapman PL; Sarr MD; Rasgon JL; Foy BD Malar J; 2010 Dec; 9():365. PubMed ID: 21171970 [TBL] [Abstract][Full Text] [Related]
17. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Pongvongsa T; Phommasone K; Adhikari B; Henriques G; Chotivanich K; Hanboonkunupakarn B; Mukaka M; Peerawaranun P; von Seidlein L; Day NPJ; White NJ; Dondorp AM; Imwong M; Newton PN; Singhasivanon P; Mayxay M; Pukrittayakamee S Malar J; 2018 Nov; 17(1):405. PubMed ID: 30390647 [TBL] [Abstract][Full Text] [Related]
18. Implementation research of a cluster randomized trial evaluating the implementation and effectiveness of intermittent preventive treatment for malaria using dihydroartemisinin-piperaquine on reducing malaria burden in school-aged children in Tanzania: methodology, challenges, and mitigation. Makenga G; Seth MD; Baraka V; Mmbando BP; Challe DP; Francis F; Mhina A; Minja DTR; Chiduo M; Mandara C; Liheluka E; Gesase S; Segeja M; Mtove G; Kamugisha M; Lusasi A; Chacky F; David A; Thawer S; Mohamed A; Lazaro S; Molteni F; Nkayamba A; Van Geertruyden JP; Lusingu JPA Malar J; 2023 Jan; 22(1):7. PubMed ID: 36609279 [TBL] [Abstract][Full Text] [Related]
19. Impact of population based indoor residual spraying with and without mass drug administration with dihydroartemisinin-piperaquine on malaria prevalence in a high transmission setting: a quasi-experimental controlled before-and-after trial in northeastern Uganda. Echodu DC; Yeka A; Eganyu T; Odude W; Bukenya F; Amoah B; Wanzira H; Colborn K; Elliott RC; Powell SE; Kilama M; Mulebeke R; Nankabirwa J; Giorgi E; Roskosky M; Omoding O; Gonahasa S; Opigo J BMC Infect Dis; 2023 Feb; 23(1):72. PubMed ID: 36747133 [TBL] [Abstract][Full Text] [Related]
20. Mass drug administration can be a valuable addition to the malaria elimination toolbox. Eisele TP Malar J; 2019 Aug; 18(1):281. PubMed ID: 31438950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]